Choroid Diseases - 23 Studies Found

Completed : Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis
:
  • Uveitis
  • Intermediate Uveitis
  • Posterior Uveitis
  • : 2013-02-05
    : Drug: triamcinolone acetonide (Triesence®) 4 mg of TRIESENCE® (triamcinolone acetonide injecta
Active, not recruiting : Study of the Safety, Tolerability, and Bioactivity of Tocilizumab On Patients With Non-infectious UVEITIS: The STOP-UVEITIS Study
:
  • Intermediate Uveitis
  • Posterior Uveitis
  • Pan-uveitis
    • : 2012-10-26
    : Drug: Tocilizumab Tocilizumab (4 mg/kg or 8 mg/kg) O
Active, not recruiting : Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert
:
  • Posterior Uveitis
  • Intermediate Uveitis
  • Panuveitis
    • : 2012-09-24
    :
    • Drug: FAI insert
    • Drug: Sham injection
Recruiting : Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis ,
:
  • Non-infectious Intermediate Uveitis
  • Non-infectious Posterior Uveitis
  • Drug: LFG316 LFG316 administer
Recruiting : Intravitreal Sirolimus as Therapeutic Approach to Uveitis
:
  • Uveitis
  • Intermediate Uveitis
  • Posterior Uveitis
  • : 2011-01-20
    :
    • Drug: Intravitreal injection 440mcg

Recruiting : Sirolimus as Therapeutic Approach to Uveitis
:
  • Uveitis
  • Intermediate Uveitis
  • Posterior Uveitis
  • : 2009-04-30
    :
    • Drug: Sirolimus (rapamycin) Wi
Completed : A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis
:
  • Uveitis, Posterior
  • Uveitis, Intermediate
  • Panuveitis
    • <
    : 2006-11-27
    :
    • Drug: Placebo PO BID
Completed : A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis
:
  • Uveitis, Posterior
  • Uveitis, Intermediate
  • Panuveitis
    • <
    : 2006-11-27
    :
    • Drug: Placebo PO BID
Recruiting : Dosing Strategy of Intravitreal Ranibizumab for Pathological Myopia Choroidal Neovascularization
: Choroidal Neovascularization
: 2016-08-21
: Drug: 0.5mg intravitreal ranibizumab Patients received ranibizumab (0.5mg, Novartis AG, Basel, Switzerla
Recruiting : Intravitreal Conbercept for Idiopathic Choroidal Neovascularization
: Idiopathic Choroidal Neovascularization
: 2016-07-27
: Drug: conbercept 0.05ml conbercept Other Name: conbe
<<< Previous | Next >>>